IL-7 binding proteins and their use in medical therapy
Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
1. A method for the treatment of an autoimmune and/or inflammatory condition in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an interleukin 7 (IL-7) binding protein or IL-7 binding fragment thereof comprising:
(i) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 6;
(ii) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 7;
(iii) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 8;
(iv) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 9;
(v) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 10; and
(vi) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 11.
2. The method of claim 1 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 4 and a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 5.
3. The method of claim 2 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5.
4. The method of claim 1 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 2 and a light chain having a sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 3.
5. The method of claim 4 , wherein the IL-7 binding protein or IL-7 binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 2 and a light chain comprising the amino acid sequence of SEQ ID NO: 3.
6. The method of claim 1 , wherein the IL-7 binding protein or IL-7 binding fragment thereof is an antibody.
7. The method of claim 6 , wherein the antibody comprises an IgG1 or IgG4 Fc region.
8. The method of claim 7 , wherein the antibody comprises a human IgG1 heavy chain constant region.
9. The method of claim 8 , wherein the antibody comprises a human IgG1 heavy chain constant region having an alanine residue at position 235 and position 237 according to EU numbering.
10. The method of claim 1 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
11. The method of claim 10 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
12. The method of claim 10 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus.
13. The method of claim 10 , wherein the autoimmune and/or inflammatory condition is inflammatory bowel disease.
14. The method of claim 10 , wherein the autoimmune and/or inflammatory condition is type 1 diabetes.
15. The method of claim 3 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
16. The method of claim 15 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
17. The method of claim 15 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus, inflammatory bowel disease, or type I diabetes.
18. The method of claim 5 , wherein the autoimmune and/or inflammatory condition is multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, systemic lupus erythematosus, or type I diabetes.
19. The method of claim 18 , wherein the multiple sclerosis is clinically isolated syndrome, relapsed remitting, primary progressive or secondary progressive.
20. The method of claim 18 , wherein the autoimmune and/or inflammatory condition is systemic lupus erythematosus, inflammatory bowel disease, or type I diabetes.